source
- Leqembi posts $184M Q2 sales, best quarter since launch, Biogen lifts guidanceLeqembi, the anti-amyloid Alzheimer’s drug co-developed by Eisai and Biogen, generated $184 million in global sales in the second quarter, according to Biogen. The Q2 figure represents the stronge…
- Former Recursion CEO Chris Gibson joins Dimension Capital as operating partnerChris Gibson, who led Recursion Pharmaceuticals for a decade, has taken a new role at venture firm Dimension Capital. At Dimension, he will serve as an operating partner, bringing his experience a…